Performing screening assays—prior to carrying out costly GLP genetox studies—allows an organization to better know the risks, costs and timetable for development of a compound, while making only a minimal investment of time and finances. There are valuable advantages, then, for companies that have several leads but need help deciding which compound to move into clinical development. Our screening assays are one way to uncover differentiators between compounds and ultimately select a development candidate.
Screening assays answer a few very basic questions: Does my test article pose a risk of genetic damage? And if so, what is it, and what risks does this add to the development project and eventual approval of a product?
Genetic toxicology screening enables a sponsor organization to lower the risk of their financial investment in drug development, while providing clear insight into the viability of its compound(s). The prospect of identifying effective compounds quickly and economically translates into a greater understanding of the mutagenicity characteristics of the compound and a higher probability for FDA submission with minimal cost to the sponsor.
In turn, a minimal investment in a screening assay often yields valuable results for a compound and its sponsor organization.
prev